Treatment outcome of 72 patients with parotid cancer

DOI Web Site 6 Citations
  • Shinomiya Hitomi
    Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine
  • Otsuki Naoki
    Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine
  • Yamashita Daisuke
    Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine
  • Shinomiya Hirotaka
    Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine
  • Teshima Masanori
    Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine
  • Ejima Yasuo
    Department of Radiation Oncology, Kobe University Graduate School of Medicine
  • Kiyota Naomi
    Department of Medical Oncology/Hematology, Kobe University Graduate School of Medicine
  • Sasaki Ryohei
    Department of Radiation Oncology, Kobe University Graduate School of Medicine
  • Nibu Ken-ichi
    Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine

Bibliographic Information

Other Title
  • 耳下腺癌72例の臨床的検討

Search this article

Abstract

Parotid cancers are relatively rare, comprising 23 pathological types with differing biological behavior. To assess the possible prognostic factors and our current treatment strategy for parotid cancers, a total of 72 patients with parotid gland cancer treated by surgery between 1994 and 2013 were retrospectively analyzed. There were 42 males and 30 females and the age ranged from 5 to 84 years old with the median age of 59. The median follow-up period was 37.5 months ranging from 3 to 208 months. Among 72 patients, 10 patients (14%), 24 patients (33%), 10 patients (14%) and 28 patients (39%) were staged as I, II, III and IVA, respectively. The most common pathological type was mucoepidermoid carcinoma in 23 patients, followed by carcinoma ex pleomorphic adenoma in 11 patients, adenoid cystic carcinoma in 9 patients, salivary duct carcinoma in 9 patients, and acinic cell carcinoma in 8 patients. All high-grade malignant tumors were preoperatively diagnosed as malignant, while 28.6% (12 of 42) of low or intermediate malignant tumors were preoperatively misdiagnosed as benign due to their benign clinical findings. Overall survival rate and disease-specific survival rate at 3 years were 81% and 82%, respectively, and those at 5 years were 79% and 82%, respectively. Multivariate analysis revealed that clinical N stage and pathological grades significantly influenced disease-specific survival.

Journal

  • Toukeibu Gan

    Toukeibu Gan 42 (1), 51-56, 2016

    Japan Society for Head and Neck Cancer

Citations (6)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top